Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD209 | Q9NNX6 | 2/20 | 0.67 |
| ▸ | TYR | P14679 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | G6PD | P11413 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15782513 | 1.00 | CD209 (0.67) | CD209TYRPOLBKDM4EGAA | |
| SCHEMBL8598153 | 1.00 | CD209 (0.67) | CD209TYRPOLBKDM4EGAA | |
| SCHEMBL1378657 | 1.00 | CD209 (0.67) | CD209TYRPOLBKDM4EGAA | |
| SCHEMBL29745897 | 1.00 | CD209 (0.67) | CD209TYRPOLBKDM4EGAA | |
| SCHEMBL219631 | 1.00 | CD209 (0.67) | CD209TYRPOLBKDM4EGAA | |
| SCHEMBL15781203 | 1.00 | CD209 (0.67) | CD209TYRPOLBKDM4EGAA | |
| SCHEMBL29386721 | 1.00 | CD209 (0.67) | CD209TYRPOLBKDM4EGAA | |
| SCHEMBL14122676 | 1.00 | CD209 (0.67) | CD209TYRPOLBKDM4EGAA | |
| Water SCHEMBL869487 | 0.99 | CD209 (0.66) | CD209TYRPOLBKDM4EGAA | |
| SCHEMBL9180381 | 0.99 | CD209 (0.65) | CD209TYRPOLBKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260114475-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME | MARS, INCORPORATED (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4344552-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY, AND METHODS FOR PREPARING THE SAME | MARS, INCORPORATED (US) | 2024-04-03 | — | — | EP | disclosed |
| US-20210346385-A1 | TASTE-MASKED DOSAGE FORMS | DEEP OCEAN CAPITAL MANAGEMENT LP | 2021-11-11 | — | — | US | disclosed |
| EP-3763419-A1 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | Anji Pharma (US) LLC (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-2661266-B1 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ANJI PHARMA (US) LLC (US) | 2020-09-16 | — | — | EP | disclosed |
| US-10610500-B2 | Chemosensory receptor ligand-based therapies | ANJI PHARMA (US) LLC (US) | 2020-04-07 | — | — | US | disclosed |
| WO-2020061584-A1 | TASTE-MASKED DOSAGE FORMS | MSB HOLDINGS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| CN-109971808-A | The method for preparing malonyl product | 北京中医药大学 | 2019-07-05 | — | — | CN | disclosed |
| US-20190038576-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2019-02-07 | — | — | US | disclosed |
| US-9962344-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-7413867-B2 | Method for the identification of antagonists of a phenylthiocarbamide/bitter taste receptor | Deutsches Institut für Ernährungsforschung, Stiftung des öffentlichen Rechts, Vertreten durch den Stiftungsvorstand (DE) | 2008-08-19 | — | — | US | disclosed |
| US-6096545-A | DNA ENCODING A PROTEIN KINASE OF A PLANT; FOR TRANSGENIC PLANTS WITH MODIFIED PHOSPHORUS METABOLISM | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2000-08-01 | — | — | US | disclosed |
| EP-0917564-A2 | PHOSPHATE STARVATION-INDUCIBLE PROTEINS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1999-05-26 | — | — | EP | disclosed |
| US-5766267-A | USING FIBER REACTIVE DYES | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-06-16 | — | — | US | disclosed |
| WO-1998005760-A2 | PHOSPHATE STARVATION-INDUCIBLE PROTEINS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1998-02-12 | — | — | WO | disclosed |
| EP-0439585-B1 | IMMOBILISATION OF LIGANDS BY RADIO-DERIVATIZED POLYMERS | MAG GEORG MAYRHOFER & CO OHG (AT) | 1997-10-29 | — | — | EP | disclosed |
| EP-0745719-A2 | Use of carbohydrate compounds as auxiliary agents in the dyeing or printing of fibrous materials | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-12-04 | — | — | EP | disclosed |
| US-5196478-A | Polystyrene, assays | EPIPHARM ALLERGIE-SERVICE GESELLSCHAFT M.B.H. (AT) | 1993-03-23 | — | — | US | disclosed |
| EP-0439585-A1 | IMMOBILISATION OF LIGANDS BY RADIO-DERIVATIZED POLYMERS. | EPIPHARM ALLERGIE SERVICE (AT) | 1991-08-07 | — | — | EP | disclosed |
| WO-1991002768-A1 | IMMOBILISATION OF LIGANDS BY RADIO-DERIVATIZED POLYMERS | EPIPHARM ALLERGIE-SERVICE GESELLSCHAFT M.B.H. (AT) | 1991-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10610500-B2 | Chemosensory receptor ligand-based therapies | TAS1R2, TAS2R1, GPR119 | CD209 2562/4885TYR 1430/4885POLB 4335/4885 |
| US-20260114475-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME | PIGS, TAS2R13, CEL | CD209 235/4885TYR 446/4885POLB 4105/4885 |
| US-20190038576-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | CD209 2562/4885TYR 1430/4885POLB 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.